Burning Rock Biotech Limited (NASDAQ:BNR) Sees Large Decline in Short Interest

Burning Rock Biotech Limited (NASDAQ:BNR) saw a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 60,500 shares, a decline of 6.6% from the December 15th total of 64,800 shares. Approximately 0.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 26,300 shares, the short-interest ratio is presently 2.3 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Burning Rock Biotech stock. SkyView Investment Advisors LLC bought a new position in shares of Burning Rock Biotech Limited (NASDAQ:BNR) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 10,000 shares of the company’s stock, valued at approximately $64,000. SkyView Investment Advisors LLC owned about 0.10% of Burning Rock Biotech at the end of the most recent reporting period. Institutional investors and hedge funds own 30.03% of the company’s stock.

Burning Rock Biotech Price Performance

Shares of Burning Rock Biotech stock opened at $6.75 on Monday. The stock has a market cap of $69.07 million, a P/E ratio of -2.25 and a beta of 0.55. The stock’s 50 day simple moving average is $6.15 and its 200-day simple moving average is $5.29. Burning Rock Biotech has a 1-year low of $2.62 and a 1-year high of $9.80.

Burning Rock Biotech Company Profile

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.